Is Alnylam Stock a Good Buy Now?

It took two solid decades for Alnylam (NASDAQ: ALNY) to carry its first new drug candidate across the finish line, but investors didn't need to wait long for the next one. The FDA approved the company's second drug just 16 months later, and the pace will probably accelerate.

Interfering with the production of troublesome proteins is working for patients with gene-driven disorders. Can shares of Alnylam work for your portfolio?

Image source: Getty Images.

Source Fool.com